Teclistamab-cqyv (Tecvayli) — CPB 1018 | AETNA Coverage Update

Aetna modified CPB 1018 for teclistamab-cqyv (Tecvayli), effective October 19, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its teclistamab-cqyv coverage policy under CPB 1018 effective October 19, 2025. The update expands initial approval criteria to include a combination regimen with talquetamab-tgvs (Talvey) — a meaningful shift that creates a new prior authorization pathway for oncology billing teams. The primary code driving reimbursement is HCPCS J9380 (teclistamab-cqyv, 0.5 mg per unit), billed alongside chemotherapy administration codes CPT 96413–96417 and infusion codes CPT 96365–96368.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Teclistamab-cqyv (Tecvayli) — CPB 1018
Policy Code	CPB 1018
Change Type	Modified
Effective Date	October 19, 2025
Impact Level	High
Specialties Affected	Hematology, Oncology, Hematology-Oncology, Infusion Centers
Key Action	Update prior authorization workflows to reflect the new combination therapy pathway with talquetamab-tgvs (J3055) before submitting claims under J9380

---

Aetna Teclistamab-cqyv Coverage Criteria and Medical Necessity Requirements 2025

The Aetna teclistamab-cqyv coverage policy sets two distinct pathways for initial approval. Understanding which pathway applies to your patient is the difference between a clean claim and a claim denial.

Pathway 1 — Single-Agent Use

Aetna considers teclistamab-cqyv medically necessary as a single agent when the member has received at least four prior therapies. Those prior therapies must include at least one drug from each of the following three categories:

#	Covered Indication Copy
1	A proteasome inhibitor (bortezomib/J9041, J9044; ixazomib; or carfilzomib/J9047)
2	An immunomodulatory agent (lenalidomide, pomalidomide, or thalidomide)
3	An anti-CD38 monoclonal antibody (daratumumab/J9145 or isatuximab/J9227)

All three categories must be documented. Missing even one — say, no anti-CD38 exposure — means the member doesn't qualify under Pathway 1. Your prior auth request needs to show prior therapy history explicitly, not just list the diagnosis.

Pathway 2 — Combination with Talquetamab-tgvs

This is the new pathway added in the October 19, 2025 update. Aetna now considers teclistamab-cqyv medically necessary in combination with talquetamab-tgvs (Talvey, J3055) when the member has received at least three prior therapies. There is no requirement that those therapies span all three drug categories.

The lower prior-therapy threshold here — three lines versus four — is significant. More patients will qualify under Pathway 2 than Pathway 1. But pairing two bispecific T-cell engagers raises toxicity questions, and your documentation should reflect that the treating oncologist has evaluated that risk.

Precertification Is Required

Prior authorization applies to all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Don't submit claims for J9380 or J3055 (in the combination setting) without an approved authorization in hand.

---

Aetna Teclistamab-cqyv Exclusions and Non-Covered Indications

Aetna is explicit: all other indications for teclistamab-cqyv are experimental, investigational, or unproven. If your oncologist is using Tecvayli outside of relapsed or refractory multiple myeloma — for any other hematologic malignancy, for earlier-line myeloma, or in combination with anything other than talquetamab-tgvs — Aetna will not cover it under this policy.

The ICD-10 code that matters here is C90.0 (multiple myeloma). Bill with C90.0 and confirm the specific subcode — not having achieved remission, in remission, or in relapse — matches the clinical documentation. That subcode determination comes from your clinical records, not from the policy source itself. C90.1 (plasma cell leukemia) and C90.2 (extramedullary plasmacytoma) appear in the CPB 1018 code table, but Aetna's coverage criteria are written specifically for multiple myeloma. Claims carrying C90.1 or C90.2 with J9380 do not map to any covered indication under current policy language.

If you're billing for a clinical trial protocol or off-label use, stop and loop in your compliance officer before submitting. The financial exposure on a bispecific antibody claim is not a place to guess.

---

Coverage Indications at a Glance

---

Aetna Teclistamab-cqyv Billing Guidelines and Action Items 2025

This policy has real teeth. A bispecific T-cell engager billed per 0.5 mg unit (J9380) adds up fast — these are not low-dollar claims. Sloppy documentation or a missed authorization will cost you.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Teclistamab-cqyv (Tecvayli) Under CPB 1018

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9380	HCPCS	Injection, teclistamab-cqyv, 0.5 mg
J3055	HCPCS	Injection, talquetamab-tgvs, 0.25 mg

Supporting HCPCS Codes (Prior Therapy Documentation Reference)

These codes represent prior therapies that must appear in the patient's treatment history to satisfy Pathway 1 criteria. You won't bill them for the current encounter, but your PA documentation needs to reference them.

CPT Administration Codes

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
C90.0	Multiple myeloma
C90.1	Plasma cell leukemia
C90.2	Extramedullary plasmacytoma

Note on ICD-10 use: Aetna's coverage criteria are written for multiple myeloma only. Bill with C90.0 and confirm the specific subcode — not having achieved remission, in remission, or in relapse — matches your clinical documentation. C90.1 and C90.2 appear in the CPB 1018 code table but do not map to any covered indication under current policy language. Your billing team should flag any claim using C90.1 or C90.2 with J9380 for compliance review before submission.

---